Published On: Wed, Oct 19th, 2016

Broker Changes For Kite Pharma, Inc. (NASDAQ:KITE)


Recently stock market analysts have updated their consensus ratings on shares of Kite Pharma, Inc. (NASDAQ:KITE).

Most recent broker ratings

10/17/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 72 price target on the stock.

10/10/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 75 price target on the stock.

10/07/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Goldman Sachs. They now have a USD 70 price target on the stock.

10/06/2016 – Kite Pharma, Inc. had its “neutral” rating reiterated by analysts at BTIG Research.

10/06/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 74 price target on the stock.

09/27/2016 – Kite Pharma, Inc. had its “equal weight” rating reiterated by analysts at Barclays. They now have a USD 65 price target on the stock.

09/27/2016 – Kite Pharma, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 78 price target on the stock.

08/09/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 77 price target on the stock.

08/09/2016 – Kite Pharma, Inc. had its “outperform” rating reiterated by analysts at Mizuho. They now have a USD 80 price target on the stock.

06/02/2016 – Raymond James began new coverage on Kite Pharma, Inc. giving the company a “outperform” rating. They now have a USD 61 price target on the stock.

03/17/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at SunTrust. They now have a USD 70 price target on the stock.

02/25/2016 – Citigroup began new coverage on Kite Pharma, Inc. giving the company a “buy” rating. They now have a USD 67 price target on the stock.

02/01/2016 – RBC Capital began new coverage on Kite Pharma, Inc. giving the company a “outperform” rating. They now have a USD 85 price target on the stock.

12/15/2015 – Kite Pharma, Inc. was upgraded to “buy” by analysts at Standpoint Research. They now have a USD 100 price target on the stock.

11/02/2015 – Kite Pharma, Inc. had its “outperform” rating reiterated by analysts at Cowen.

Kite Pharma, Inc. has a 50 day moving average of 55.87 and a 200 day moving average of 52.55. The stock’s market capitalization is 2.46B, it has a 52-week low of 38.41 and a 52-week high of 89.84.

The share price of the company (NASDAQ:KITE) was up +0.32% during the last trading session, with a high of 50.14 and the volume of Kite Pharma, Inc. shares traded was 1332654.

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.